Stocktoria
CUMBERLAND PHARMACEUTICALS INC CPIX
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2009-08-11
CUMBERLAND PHARMACEUTICALS INC financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44.5M | $37.9M | $39.6M | $42.0M | $36.0M | $37.4M | $34.4M | $29.3M | $41.2M | $33.0M |
| R&D expense | $5.6M | $4.8M | $5.8M | $6.7M | $5.7M | $5.8M | $6.9M | $7.6M | $4.3M | $3.2M |
| Operating income | -$2.8M | -$6.4M | -$9.6M | -$5.7M | -$7.7M | -$6.4M | -$9.3M | -$11.2M | -$4.1M | -$1.4M |
| Interest expense | $495,990 | $605,508 | $667,861 | $585,995 | $98,031 | $263,627 | $246,186 | $195,848 | $92,904 | $106,392 |
| Income tax | $40,256 | -$22,669 | $45,769 | $68,850 | $34,891 | $55,902 | -$79,316 | $16,636 | $4.2M | -$330,924 |
| Net income | -$2.8M | -$6.5M | -$6.3M | -$5.6M | -$3.5M | -$3.3M | -$3.5M | -$7.0M | -$8.0M | -$944,683 |
| EPS (diluted) | $-0.19 | $-0.46 | $-0.44 | $-0.38 | $-0.24 | $-0.22 | $-0.23 | $-0.45 | $-0.50 | $-0.06 |
| Operating cash flow | $4.9M | -$612,186 | $6.1M | $8.5M | $6.3M | $5.4M | $3.1M | $3.1M | -$557,714 | $569,478 |
| Free cash flow | $4.8M | -$678,647 | $5.8M | $8.4M | $6.2M | $5.3M | $2.8M | $2.7M | -$833,674 | $438,606 |
| Cash & equivalents | $11.4M | $18.0M | $18.3M | $19.8M | $27.0M | $24.8M | $28.2M | $27.9M | $45.4M | $34.5M |
| Inventory | $29,935 | $4.0M | $4.6M | $9.9M | $8.4M | $10.6M | $8.9M | $12.1M | $6.7M | $5.4M |
| Total assets | $76.8M | $75.6M | $81.8M | $92.9M | $84.5M | $96.5M | $104.5M | $112.7M | $93.2M | $93.4M |
| Total liabilities | $52.3M | $53.0M | $52.5M | $57.0M | $41.9M | $49.6M | $53.5M | $57.1M | $29.3M | $20.3M |
| Shareholders' equity | $24.9M | $22.9M | $29.6M | $36.3M | $42.8M | $47.0M | $51.1M | $55.8M | $64.1M | $73.2M |
Growth · year-over-year · Revenue CAGR 3.4%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +17.6% | -4.3% | -5.9% | +16.7% | -3.9% | +8.9% | +17.2% | -28.7% | +24.6% | -1.5% |
| Net income growth | — | — | — | — | — | — | — | — | — | -229.2% |
| EPS growth | — | — | — | — | — | — | — | — | — | -250.0% |
| Free cash flow growth | — | -111.7% | -30.4% | +33.9% | +18.3% | +87.7% | +5.8% | — | -290.1% | -92.4% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.